| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | VP Fin & Chief Acct Officer
2 companies
Steffen Pietzke last filed a Form 4 in July 2023, as Chief Financial Officer at ENVX. The filings on record cover 2 companies. Steffen Pietzke's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 621,385 shares of ENVX.
Steffen Pietzke has 28 Form 4 filings on record from July 2020 to July 2023, across 2 companies: Chief Financial Officer at Enovix (ENVX), 2022–2023; VP Fin & Chief Acct Officer at Alx Oncology (ALXO), 2020.
The 33 reported transactions were 24 tax withholdings, 7 stock awards, 1 open-market purchase and 1 option or other derivative award.
Counted by filing, the open-market trades come to 1 purchase worth about $57K and no sales.
The only open-market purchase was 3,000 shares of ALXO at an average $19.00 on July 21, 2020, about $57K.
Shares as reported in the last Form 4 for each company; the most recent is from July 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2020 | ALXO Alx Oncology Holdings Inc | VP Fin & Chief Acct Officer | Buy | 3,000 | $19.00 | $57,000.00 | New |